EZH2 and B-cell chronic lymphocytic leukemia: Specifically, we attempted to reproduce the analysis of Kosalai et al. (Kosalai et al., 2019) on samples that originate from the peripheral blood of M- and U-CLL patients and were subjected to immunoprecipitation for EZH2 methyltransferase and H3K27me3 histone modification, to identify sites where EZH2 binds and catalyzes the H3K27me3 modification with different efficiency between the aggressive U-CLL (n = 6) and the more indolent M-CLL (n = 6) (Kosalai et al., 2019).